Monday, May 23, 2022

AstraZeneca hits U.K. antitrust roadblock with $39B Alexion buy despite U.S. FTC clearance


AstraZeneca investors breathed a sigh of relief last month when the U.S. antitrust watchdog cleared the company’s proposed $39 billion acquisition of Alexion Pharma. Turns out, that go-ahead was no guarantee of a regulatory free pass ahead.

Tuesday, the U.K.’s Competition and Markets Authority (CMA) said it has launched an anti-competition investigation into the AstraZeneca-Alexion deal.

The agency wonders whether the transaction would hurt competition “within any market or markets in the United Kingdom,” it said in a notice.

The CMA is now soliciting public comments until June 3 to help with its evaluation and aims to reach a decision by July 21. If, at that time, the agency found any reason to believe a “realistic prospect” of threats to competition, it may launch a more in-depth, phase 2 assessment that may last up to 24 weeks or even 32 weeks in special circumstances, according to the CMA rules.

For months, industry watchers have been watching for increased deal-making scrutiny from the U.S. Federal Trade Commission (FTC). In March, the U.S. antitrust authority launched a review of its current product-by-product approach to evaluating biopharma M&A. The FTC, now led by Democrats after last year’s election, said a rise in mega deals such as those between Bristol Myers Squibb and Celgene could be contributing to high drug prices and anti-competitive behaviors such as pay-for-delay settlements.

RELATED: Surprise: AstraZeneca’s $39B Alexion buy clears a newly vigilant FTC without a hitch

But to pharma watchers’ surprise, the FTC last month blessed the Alexion takeover without raising any issues. Still, the FTC’s initiative includes a collaboration with competition authorities in other countries.

As Jeny Maier, a partner at law firm Axinn, Veltrop & Harkrider, pointed out during a recent interview, the FTC has to convince a federal judge to block a merger, while its counterparts elsewhere can block M&A deals by themselves. So if the FTC and other regulators—the CMA, for example—agreed that a proposed deal would hurt competition, the U.S. agency may be able to bypass the onerous legal fighting and get its intended outcome by simply letting other jurisdictions block the deal, she said.

RELATED: FTC’s crackdown on pharma mergers reflects ‘tougher’ M&A environment under Biden administration: lawyer

For AZ’s part, the drugmaker has pictured the Alexion deal as a way to establish a strong presence in rare disease and immunology beyond its current focus in oncology and cardiovascular and metabolic diseases. Both companies’ shareholders have approved the transaction. AZ has stated that it intends to wrap up the deal in the third quarter.

In addition to the U.S., the deal has snagged green lights from competition authorities in Brazil, Canada, Russia and Japan, among others, according to AZ. Besides the U.K., other notable missing decisions include the EU and China.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...